Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâ€™s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Employees

Sector

Biotechnology & Medical Research

More about the company

25-07-01	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
25-07-01	Oncternal Therapeutics, Inc. Announces Management Changes	CI
24-12-04	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index	CI
24-12-01	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index	CI
24-11-25	Top Premarket Decliners	MT
24-11-06	Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-23	Oncternal Therapeutics Continues to Explore Strategic Alternatives	CI
24-10-22	Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
24-09-12	Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534	CI
24-09-12	Oncternal Therapeutics, Inc. Announces Workforce Reduction	CI
24-09-12	Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024	CI
24-09-12	Sector Update: Health Care Stocks Rise in Thursday Trading	MT
24-09-12	Oncternal Therapeutics Announces Exploration of Strategic Alternatives	CI

24-09-12	Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	MT
24-04-15	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT
23-12-04	Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	MT
23-09-18	HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	MT
23-04-04	Maxim Downgrades Oncternal Therapeutics to Hold From Buy	MT

25-03-07	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC	AQ
24-11-25	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
24-10-22	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
24-09-12	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives	AQ
24-08-08	Oncternal Therapeutics: Q2 Earnings Snapshot	AQ

3 years	0.53	13.14
5 years	0.53	89.8
10 years	0.53	211.2

Manager	Title	Age	Since
Richard Vincent DFI	Director of Finance/CFO	63	2017-03-31
Yisrael Katz CTO	Chief Tech/Sci/R&D Officer	-	2023-06-30
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	53	-

Oncternal Therapeutics, Inc. Stock

Stocks

ONCT

US68236P2065

Biotechnology & Medical Research

Latest news: Oncternal Therapeutics, Inc.

Analysts' recommendations: Oncternal Therapeutics, Inc.

Press Releases: Oncternal Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Oncternal Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Director	Title	Age	Since
Dan Kisner BRD	Director/Board Member	79	2019-06-06
Rosemary Mazanet BRD	Director/Board Member	70	2021-01-26
William LaRue BRD	Director/Board Member	75	2017-11-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/20/24	Michael Carter	Free	Director	2,200	0.0743%
6/20/24	Charles Theuer	Free	Director	2,200	0.0743%
6/20/24	Dan Kisner	Free	Director	2,200	0.0743%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCTERNAL THERAPEUTICS, INC.	-24.11%	-.--%	-	-	1.56M
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	64.14B
ARGENX SE	+0.90%	+2.66%	+12.22%	+83.86%	55.53B
LONZA GROUP AG	+1.11%	+0.76%	+11.92%	+103.21%	53.03B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	45.99B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	42.45B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	40.45B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.25B
GENMAB A/S	-3.45%	+38.92%	+98.33%	+85.18%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-3.02%	-0.75%	+22.80%	-11.05%	24.23B
Average	-2.16%	+4.08%	+51.51%	+161.72%	43.62B
Weighted average by Cap.	+0.59%	+3.49%	+48.67%	+159.75%